Tom Miller describes the rationale for the raise and what it will allow Iambic to do, how he believes the company's AI approach is unique

Yvonne Greenstreet shares her thoughts on key points of today's top-line, but as monotherapy and in combination, the potential market, and w

Luca Issi gives his take on the sector and discusses news regarding Moderna, Caribou, Ultragenyx, Biomarin, Alnylam, Lexeo, and Wave Life...

Michael McElhaugh describes data presented at EASL for the RNAi therapeutics imdusiran, explains the rationale for the PD-L1, and more.

Mike Ehlers describes how this $42M upfront and up to $1.8B in potential milestones deal is focused on neurological conditions, how RNA...

Cardiology expert Ethan Weiss describes the difference between ANGPTL4 and ANGPLT3, the rationale for lowering remnant cholesterol,...

Amy Brown will be covering biotech news and research in the London-Oxford-Cambridge triangle area for BiotechTV.

CEO Lisa Deschamps describes this now clinical program for frontotemporal dementia, and Aviado's broader platform for using gene...

Rahul Dhanda describes the technology that Syntis uses to coat the upper region of the small intestine to modulate nutrient uptake, and...

After announcing a partnership expansion with Ipsen on Friday, Zhen Su describes how to succeed against cold tumors where T-cells are not...

Kevin Lind explains how patients randomized to therapy and placebo crossover patients are seeing comparable reductions in seizure levels....

Sushil Patel describes Replimune's ASCO and follow-on data from last week in the context of PD-1 response rates and competitor data from...

Co-Founder Aravind Krishnan describes the scientific idea behind ToxiSense, and how the Philadelphia-based Science Center's Founders...

Paula Ragan describes the launch of this medicine that was approved at the end of April and previews an upcoming data announcement X4...

Joseph Payne describes data from the first four patients with CF to receive this inhaled mRNA at #ECFS2024. He also summarizes Arcturus'...

Daniel Oliver describes how Rejuvenate believes this program could have utility against arrhythmias and heart failure in both humans and...

Salim Syed gives his take on Cytokinetics, BridgeBio, Enliven, Vaxcyte, and Wave Life Sciences.

Will Lewis describes last week's data and what means not just for bronchiectasis but also as a broader proof of concept for DPP1...